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Available online 12 June 2017Ataxia telangiectasia (A-T) is a neurodegenerative autosomal recessive disorder with the main characteristics of
progressive cerebellar degeneration, sensitivity to ionizing radiation, immunodeﬁciency, telangiectasia, prema-
ture aging, recurrent sinopulmonary infections, and increased risk of malignancy, especially of lymphoid origin.
Ataxia Telangiectasia Mutated gene, ATM, as a causative gene for the A-T disorder, encodes the ATM protein,
which plays an important role in the activation of cell-cycle checkpoints and initiation of DNA repair in response
to DNA damage. Targeted next-generation sequencing (NGS) was performed on an Iranian 5-year-old boy pre-
sented with truncal and limb ataxia, telangiectasia of the eye, Hodgkin lymphoma, hyper pigmentation, total al-
opecia, hepatomegaly, and dysarthria. Sanger sequencingwas used to conﬁrm the candidate pathogenic variants.
Computational dockingwas done using the HEX software to examine how this change affects the interactions of
ATM with the upstream and downstream proteins. Three different variants were identiﬁed comprising two ho-
mozygous SNPs and one novel homozygous frameshift variant (c.80468047delTA, p.Thr2682ThrfsX5), which
creates a stop codon in exon 57 leaving the protein truncated at its C-terminal portion. Therefore, the activation
and phosphorylation of target proteins are lost. Moreover, the HEX software conﬁrmed that themutated protein
lost its interaction with upstream and downstream proteins. The variant was classiﬁed as pathogenic based on
the American College ofMedical Genetics andGenomics guideline. This study expands the spectrumofATMpath-
ogenic variants in Iran and demonstrates the utility of targeted NGS in genetic diagnostics.
© 2017 Published by Elsevier B.V.Keywords:
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Iran1. Introduction
Ataxia telangiectasia (A-T)(MIM_208900), as an autosomal reces-
sive cerebellar ataxia [1], has been described with different characteris-
tics such as progressive cerebellar degeneration, sensitivity to ionizing
radiation, immunodeﬁciency, telangiectasia, premature aging, recurrent
sinopulmonary infectious, increased risk of malignancy, especially of
lymphoid origin, poor growth, gonadal atrophy, delayed pubertal
development, and insulin-resistant diabetes [2]. The worldwide
frequency of A-T is estimated to be between 1 in 40,000 and 1 in
100,000 live births [3].etics, School of Medicine, Ahvaz
mmadi-Asl).A-T occurs as a result of mutation within ATM (MIM# 607585). The
gene, previously mapped to the chromosomal region 11q22-23 [4],
was identiﬁed by Savitsky et al. [5]. ATM is a large gene with 66 exons,
which spreads over 150 kb of genomic DNA [6,7], and encodes a protein
with 3050 residues. It is amember of phosphoinositide 3-kinase-related
protein kinase super family. Although the ATM protein is predominant-
ly located in the nucleus, it has also been detected in peroxisomes-asso-
ciated cytosol [8]. This protein is composed of different conserved
domains, including TAN, FAT, PIKKc_ATM, and FATC (https://www.
ncbi.nlm.nih.gov/). It exists in cells as an inactive dimer. Radiations
resulting in the double- strand break stimulate auto-phosphorylation
of ATM on Ser-1981 and its activation. Tip60 acetylates the FATC do-
main of ATM in response to a change in chromatin structure following
DNA damage to upregulate the kinase activity of the ATM protein. Acti-
vated ATM could phosphorylate downstream proteins such as p53,
BRCA1, MDM2, CHECK2, NBS1, RAD17, MRE11, SMC1, TRF2, and
Table 1
A list of the variants identiﬁed in the ATM gene and their frequencies.
Variant Name RS-ID Frequency in
dbSNPa Hapmapb 1000-genomec BGI'sd
p.Asp1853Asn rs1801516 0.006 0 0.0128 0
p.Asn1983Ser rs659243 1 0.992 1 1
p.Thr2682ThrfsX5 Novel – – 0 0
a dbSNP: SNP frequency in the dbSNP database.
b Hapmap: SNP frequency in Asian population in the Hapmap database.
c 1000-genome: SNI' frequency in all the samples from the 1000 Genome Project.
d BGI's: SNP frequency in 961′s local ‘200 people genome database.
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repair [9,10].
Out of all ATM pathogenic variants which are almost 800 so far
(http://www.hgmd.cf.ac.uk/ac/index.php), truncating variants are the
most common variants which are likely to create highly unstable pro-
tein fragments [11,12]. Pathogenic variants have been spread uniformly
over the coding region of the ATM, and no mutational hotspot has been
identiﬁed in this gene [13].
Next-generation sequencing (NGS) is a fast and cost-effective se-
quencing technology through which millions of DNA sequence reads
are generated in a single run. It has revolutionized theway genome var-
iations are identiﬁed for genetic disease [14,15].
There are few reports of pathogenic variants in the ATM gene from
the Iranian population [16]. In this study, we applied NGS to themolec-
ular diagnosis of A-T in an Iranian patient and report a novel pathogenic
variant.
2. Materials and methods
2.1. Subjects
A 5-year-old boy with the clinical presentation of A-T, born to an
Iranian consanguineous family of Persian descent, was referred to
Ahvaz Noor Medical Genetics Laboratory in Ahvaz, Southwest Iran.
Genetic evaluation showed the truncal and limb ataxia
oculocutaneous telangiectasia, Hodgkin's lymphoma, hyperpigmen-
tation, total alopecia, hepatomegaly and dysarthria. Noticeably, the
elder son of this family was also an A-T patient and showed the
same symptoms, at the age of 3.5 years old, as the proband but
more severely affected. He died at the age of 8 due to the respiratory
failure caused by themetastasis of Hodgkin's lymphoma to the lungs.
The primary clinical diagnosis for the proband was mainly based
upon the symptoms of progressive cerebellar ataxia, dysarthria,
and telangiectasia of the eye which was the same as his elder
brother. The proband showed elevated levels of serumα-fetoprotein
(=150.30 ng/ml), alkaline phosphatase (+1505), creatinine
(=226), and also showed altered immunoglobulin proﬁles (lgG =
7.42 g/l, lgA b 0.6 g/l, lgM = 2.44 g/l, IgE b 0.1 g/l), but no cerebellar
atrophy was detected. The parents were clinically unaffected
without any neurological impairment, and had no familial history
other than their children. The family signed a written consent form
before undergoing the genetic test. The study was approved by the
Review Board of Isfahan University of Medical Sciences.
2.2. DNA extraction and mutation screening via NGS
Based on PAXgene Blood DNA Kit (QIAGEN, Germany) protocol,
genomic DNA from blood samples was extracted and assessed in
terms of quality and quantity using agarose gel and a Nanodrop
2000 instrument (Thermo Fisher Scientiﬁc Inc., USA), respectively.
The NGS test was performed using a custom-designed Nimblegen
chip capturing the fragments, including exons, splice sites, and the
adjacent intron sequences within the ATM gene. First, for sample en-
richment, fragmentation and polishing of genomic DNA were done.
Then, linkers were ligated to the fragmented samples. When array
hybridization was completed, the fragments of interest were washed
from the array using a target fragment elution wash. Following en-
richment of the ATM gene, sequencing was performed using
HiSeq2000 instrument (Illumina, San Diego, CA) with the 90 bp
pair-end reads. The variant analysis was performed via mapping
the sequence read to the reference genomic DNA (UCSC hg19)
using the Burrows-Wheeler alignment software. GATK software
was used to identify SNPs and indels [17]. Then, the identiﬁed
variants (frequency N 1%) and synonymous substitutions were ﬁl-
tered out applying public databases, including 1000 Genome Project
(http://www.1000genomes.org), HapMap samples, and dbSNP.2.3. The 3-D structure of the ATM protein and computational docking
SWISS-MODEL was used to predict the 3D structure of the ATM pro-
tein, and its truncated form based upon the homology modeling meth-
od. To predict the effect of the ATM frameshift variant on its function,
ATM interaction through its C-terminal with some proteins such as
TIP60 and p53 [9,10] was examined via docking stimulation using the
Hex software. The PDB ﬁle of the two proteins is needed as an input.
Then, the energy of two-protein interaction was calculated known as
Etot. Etot is the total calculated interaction energy of the system [18].
2.4. Co-segregation study and pathogenicity examination
The co-segregation of the variant with the A-T phenotype was done
using Sanger sequencing for the proband and othermemberswithin the
family in order to analyze the variant reported via NGS. A set of primer
was designed via Primer 3 software (F: 5′-ACACCCGGCCTAAAGTTGTA-
3′ and R: 5′-CAAAATCCCAAATAAAGCAGAAA-3′) to amplify the region
of small deletion in exon 57 of all family members. Then, the amplicon
was subject to bidirectional Sanger sequencing using an ABI 3130 auto-
mated sequencer. The sequences were compared with the ATM gene
reference sequence. Based on the criteria introduced by the American
College of Medical Genetics and Genomics (ACMG) guideline [19], the
pathogenicity of the frameshift variant in ATM gene was examined.
3. Results
3.1. Molecular ﬁnding
TargetedNGS for exons and exon-intron boundaries of the ATM gene
was performed for an affected member of the A-T family. The test plat-
formwas examined over the 95% of the ATM gene with sensitivity over
99%. Pointmutation,micro-insertion, deletion and duplication (b20 bp)
were simultaneously detected. As a result, three different variants were
detected (Table 1); two homozygous substitution variants
(p.Asp1853Asn and p.Asnl983Ser), and a small frameshift deletion
(c.8046_8047delTA, p.Thr2682ThrfsX5). Based on data provided in the
NCBI Clinvar database, both homozygous substitution variants are
benign, while the p.Asp1853Asn variant in combination with IVS38-8
TNC in cis position is possibly associated with bilateral breast cancer
[20]; it also predicts late ﬁbrosis after radiotherapy in cancer patients
[21].
According to the ACMG guideline, this variant (c.8046_8047delTA,
p.Thr2682ThrfsX5) is predicted to be pathogenic based on some lines
of evidence; Very strong (PVS1): it is a null variant in the ATM gene in
which loss of function is a known mechanism of disease. Supporting
(PP1): the co-segregation study using the Sanger sequencing method
reveals that the variant is co-segregatingwith the disease (Fig. 1). Mod-
erate (PM2): this variant is absent from the controls of the Exome Se-
quencing Project, 1000 Genomes Project, or Exome Aggregation
Consortium database. The novelty of this variant was also examined
using international mutation and polymorphism databases such as
HGMD Database, Swissvar, OMIM, ensemble, ClinVar. After elucidating
the pathogenicity of the variant, during her third pregnancy, themother
Fig. 1. a. The result of co-segregation study using Sanger sequencing. The variant is shown
by an arrow. The affected member (II-2) is homozygous for the variant and both parents
and the fetus are heterozygous. b. family pedigree showing two affected sons and a
heterozygous carrier detected via prenatal diagnosis (marked P).
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gous for the ATMmutation, the fetus was predicted to be unaffected by
A-T which was conﬁrmed after birth (the rhombic symbol in Fig. 1).
3.2. 3D structure of ATM and its truncated form
The 3D structure modeling of the ATM protein using SWISS-
MODEL shows that this protein has missed a number of its residues
including PIKK and FATC domains. The acetylation of the FATC
domain in the C-terminal portion is a primary step for the activation
of the ATM protein. Thus, deletion of the C-terminal portion could
remarkably change its structure, and disrupt its activation during
double-strand break (Fig. 2).
3.3. Truncated ATM could not get activated in DNA damage response
Truncated ATM fails to interact with Tip60, as an upstream protein,
and p53, as a downstream protein. The novel frameshift variant was ex-
amined to determine how it could affect the ATM function through its
interactions with other proteins. The Etot docking scores of the truncat-
ed and the normal ATM proteins are signiﬁcantly different; the interac-
tion of the truncated protein with the target proteins requires much
more energy (Fig. 3), leading to disrupted interactions with upstream
and downstream proteins such as TIP60 and p53, respectively. There-
fore, the dimer-monomer transition does not occur as the result of
disrupted interaction with TIP60. Alternatively, ATM cannot phosphor-
ylate its target proteins without its kinase domain, which forms whenFig. 2. 3-D structure of the ATM protein and its truncated form.the C- and N-terminal portions of ATM get together. The net result is
the failure of the truncated ATM protein to activate the proteins in-
volved in cell cycle checkpoints and DNA repair processes.
4. Discussion
This study applies the targeted NGS to A-T disorder and reports a
new frameshift variant (c.8046_8047delTA, p.Thr2682ThrfsX5) in the
ATM gene from a 5-year-old proband presented with A-T clinical fea-
tures born to a consanguineous family. This new frameshift variant re-
sults in early termination in exon 57 to produce a truncated protein.
This variant makes the protein lose its C-terminal portion, including
PIKK and FACT domains, which are necessary for its activation in re-
sponse to radiation. The variant was categorized as pathogenic based
on the ACMG guideline [19].
Activation of downstream proteins in response to double-strand
break depends on ATM activation via dimer-monomer transition fol-
lowing its auto-phosphorylation [22]. TIP60 is an upstream protein in
this pathway, which activates ATM, and makes its interaction domain
accessible for its target proteins. Dimer-monomer transition occurs
through acetylation of ATM in the FATC domain [9,23]. Thus, the inter-
action disruption could inevitably affect the function of the protein.
The mentioned frameshift deletion variant prevents the ATM protein
from interacting with TIP60, thereby inhibiting its auto-phosphoryla-
tion. Even if the protein can auto-phosphorylate, deletion of the PIKK
domain within the ATM protein disables the phosphorylation of target
proteins in response to radiation since the process requires the assem-
bly of both C-terminal and N-terminal portions [22].
ATM is a large gene with 66 small exons with nomutational hotspot
[13]. In order to save time and energy, we applied an accurate and cost-
effective diagnostic method which examines all exons and exon-intron
boundaries of ATM genes in a proband with the clinical presentation of
A-T. A novel frameshift variant was identiﬁed using NGS method locat-
ed in exon 57 resulting in protein truncation. So far, 12 pathogenic var-
iants related to A-T have been reported in this exon (9 missense
variants: Tyr2677Cys, Thr2682Ser, Pro2699Leu, Lys2700Asn,
Ile2702Arg, Cys2704Arg, Asp2708Glu, Val2716Ala; one frameshift vari-
ant; Ile2702fs; two nonsense variants: Lys2700Ter, Gln2714Ter) [24–
32].
Frameshift and nonsense variant are among the majority types of
ATM variants [11,28,33,34] constituting about 70% of A-T case [35].
This suggests that the A-T classical phenotype is due to null alleles
resulting in total loss of protein function. Truncating variants, which
lead to complete absence of ATM kinase activity lead to severe pheno-
types [36], while typical [28] or milder [37,38] phenotypes are due to
missense variants in the ATM gene.
Cerebellar ataxia is one of the manifestations in A-T as well as some
other neurodegenerative disorders. On the other hand, in these neuro-
degenerative disorders, loss of function of DNA-repair components is
common. Therefore, it suggests that a normal cerebellar development
needs an intact DNA damage response system [39].
Based on evidence provided in the ACMG guideline, the reports of
truncating variants downstream of the extreme 3 prime of an identiﬁed
truncating variant are conﬁrmatory for its pathogenicity [19]. This novel
variant causes the protein to gain early stop codon in exon 57 resulting
in A-T classical phenotype. This suggests that it is a loss-of-function var-
iant. Also, there are other null variants, related to the A-T phenotype,
downstream of this variant, which result in truncated proteins
(c.8266ANT, c.8283-8284delTC, c.8307GNA, c.8373CNA, c.8287CNT,
c.8793TNA, c.8833delCT, c.8879GNA, c.9139CNT, c.9026TNG).
In a study in China, 12novel variantswere reported from8unrelated
families with no presence of a homozygous and founder effect variant.
This provides a clue for the diversity of Chinese population and the of
ATM variants [40]. In contrast, many founder mutations have been
detected in Norwegian, Costa Rican, Polish, Italian and Amish/Menno-
nite population through haplotype analysis [13]. The similarity of 55%
Fig. 3. Bonding energies and interactions between the ATM protein and its upstream and downstream proteins, including a) TIP60, b) TP53 in cartoons (upper images) and harmonic
surface (lower images) models.
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idence of founder effect [41].With the high rate of consanguinity in Iran
(38.6%) [42], founder ATM variants are predicted to existmore frequent-
ly, and this could facilitate the diagnostics by developing a rapid and
cost-effective method to detect the pathogenic variant.
In conclusion, our study expands the spectrum of ATM pathogenic
variants in Iran and conﬁrms the utility of targeted NGS sequencing in
genetic diagnosis.
Acknowledgement
This work was supported by Ahvaz Noor Genetics Laboratory and
Isfahan University of Medical Sciences (grant no. 195122).
References
[1] M. Anheim, C. Tranchant, M. Koenig, The autosomal recessive cerebellar ataxias,
New Engl. J. Med. 366 (2012) 636–646.
[2] A. Nissenkorn, Y. Levy-Shraga, Y. Banet-Levi, A. Lahad, I. Sarouk, D. Modan-Moses,
Endocrine abnormalities in ataxia telangiectasia: ﬁndings from a national cohort,
Pediatr. Res. 79 (2016) 889–894.
[3] M. Swift, D. Morrell, E. Cromartie, A.R. Chamberlin, M.H. Skolnick, D.T. Bishop, The
incidence and gene frequency of ataxia-telangiectasia in the United States, Am. J.
Hum. Genet. 39 (1986) 573–583.
[4] R.A. Gatti, I. Berkel, E. Boder, G. Braedt, P. Charmley, P. Concannon, F. Ersoy, T.
Foroud, N.G. Jaspers, K. Lange, et al., Localization of an ataxia-telangiectasia gene
to chromosome 11q22-23, Nature 336 (1988) 577–580.
[5] K. Savitsky, A. Bar-Shira, S. Gilad, G. Rotman, A single ataxia telangiectasia gene with
a product similar to Pl-3 kinase, Science 268 (1995) 1749.
[6] T. Uziel, K. Savitsky, M. Platzer, Y. Ziv, T. Helbitz, M. Nehls, T. Boehm, A. Rosenthal, Y.
Shiloh, G. Rotman, Genomic organization of the ATM gene, Genomics 33 (1996)
317–320.
[7] M. Platzer, G. Rotman, D. Bauer, T. Uziel, K. Savitsky, A. Bar-Shira, S. Gilad, Y. Shiloh,
A. Rosenthal, Ataxia-telangiectasia locus: sequence analysis of 184 kb of human ge-
nomic DNA containing the entire ATM gene, Genome Res. 7 (1997) 592–605.
[8] D.Watters, P. Kedar, K. Spring, J. Bjorkman, P. Chen, M. Gatei, G. Birrell, B. Garrone, P.
Srinivasa, D.I. Crane, M.F. Lavin, Localization of a portion of extranuclear ATM to per-
oxisomes, J. Biol. Chem. 274 (1999) 34277–34282.
[9] Y. Sun, X. Jiang, S. Chen, N. Fernandes, B.D. Price, A role for the Tip60 histone acetyl-
transferase in the acetylation and activation of ATM, Proc. Natl. Acad. Sci. U. S. A. 102
(2005) 13182–13187.
[10] R. Kitagawa,M.B. Kastan, The ATM-dependent DNA damage signaling pathway, Cold
Spring Harb. Symp. Quant. Biol. 70 (2005) 99–109.
[11] A. Li, M. Swift, Mutations at the ataxia-telangiectasia locus and clinical phenotypes
of A–T patients, Am. J. Med. Genet. 92 (2000) 170–177.
[12] N. Sandoval, M. Platzer, A. Rosenthal, T. Dörk, R. Bendix, B. Skawran, M. Stuhrmann,
R.-D. Wegner, K. Sperling, S. Banin, Characterization of ATM gene mutations in 66
ataxia telangiectasia families, Hum. Mol. Genet. 8 (1999) 69–79.
[13] M. Telatar, S. Teraoka, Z. Wang, H.H. Chun, T. Liang, S. Castellvi-Bel, N. Udar, A.-L.
Borresen-Dale, L. Chessa, E. Bernatowska-Matuszkiewicz, Ataxia-telangiectasia:
identiﬁcation and detection of founder-effect mutations in the ATM gene in ethnic
populations, Am. J. Hum. Genet. 62 (1998) 86–97.
[14] E.R. Mardis, The impact of next-generation sequencing technology on genetics,
Trends Genet. 24 (2008) 133–141.
[15] S. De Keulenaer, J. Hellemans, S. Lefever, J.-P. Renard, J. De Schrijver, H. Van de
Voorde, M.A. Tabatabaiefar, F. Van Nieuwerburgh, D. Flamez, F. Pattyn, Molecular di-
agnostics for congenital hearing loss including 15 deafness genes using a next gen-
eration sequencing platform, BMC Med. Genet. 5 (2012) 17.
[16] M. Babaei, M. Mitui, E.R. Olson, R.A. Gatti, ATM haplotypes and associatedmutations
in Iranian patients with ataxia–telangiectasia: recurring homozygosity without a
founder haplotype, Hum. Genet. 117 (2005) 101–106.[17] H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler
transform, Bioinformatics 25 (2009) 1754–1760.
[18] G. Macindoe, L. Mavridis, V. Venkatraman, M.D. Devignes, D.W. Ritchie, HexServer:
an FFT-based protein docking server powered by graphics processors, Nucleic
Acids Res. 38 (2010) W445–W449.
[19] S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster,W.W. Grody, M. Hegde, E.
Lyon, E. Spector, K. Voelkerding, H.L. Rehm, A.L.Q.A. Committee, Standards and
guidelines for the interpretation of sequence variants: a joint consensus recommen-
dation of the American College of Medical Genetics and Genomics and the Associa-
tion for Molecular Pathology, Genet. Med. 17 (2015) 405–424.
[20] K. Heikkinen, K. Rapakko, S.M. Karppinen, H. Erkko, P. Nieminen, R. Winqvist, Asso-
ciation of common ATM polymorphism with bilateral breast cancer, Int. J. Cancer
116 (2005) 69–72.
[21] Y. Zhang, Z. Liu, M. Wang, H. Tian, K. Su, J. Cui, L. Dong, F. Han, Single nucleotide
polymorphism rs1801516 in ataxia telangiectasia-mutated gene predicts late ﬁbro-
sis in cancer patients after radiotherapy: a PRISMA-compliant systematic review
and meta-analysis, Medicine 95 (2016).
[22] N. Fernandes, Y. Sun, S. Chen, P. Paul, R.J. Shaw, L.C. Cantley, B.D. Price, DNA damage-
induced association of ATM with its target proteins requires a protein interaction
domain in the N terminus of ATM, J. Biol. Chem. 280 (2005) 15158–15164.
[23] X. Jiang, Y. Sun, S. Chen, K. Roy, B.D. Price, The FATC domains of PIKK proteins are
functionally equivalent and participate in the Tip60-dependent activation of DNA-
PKcs and ATM, J. Biol. Chem. 281 (2006) 15741–15746.
[24] G. Barone, A. Groom, A. Reiman, V. Srinivasan, P.J. Byrd, A.M. Taylor, Modeling ATM
mutant proteins from missense changes conﬁrms retained kinase activity, Hum.
Mutat. 30 (2009) 1222–1230.
[25] S.G. Becker-Catania, G. Chen, M.J. Hwang, Z. Wang, X. Sun, O. Sanal, E. Bernatowska-
Matuszkiewicz, L. Chessa, E.Y. Lee, R.A. Gatti, Ataxia-telangiectasia: phenotype/ge-
notype studies of ATM protein expression, mutations, and radiosensitivity, Mol.
Genet. Metab. 70 (2000) 122–133.
[26] S. Cavalieri, A. Funaro, P. Porcedda, V. Turinetto, N. Migone, R.A. Gatti, A. Brusco, ATM
mutations in Italian families with ataxia telangiectasia include two distinct large ge-
nomic deletions, Hum. Mutat. 27 (2006) 1061.
[27] I. Demuth, V. Dutrannoy, W. Marques, H. Neitzel, D. Schindler, P.S. Dimova, K.H.
Chrzanowska, V. Bojinova, H. Gregorek, L.M. Graul-Neumann, New mutations in
the ATM gene and clinical data of 25 AT patients, Neurogenetics 12 (2011) 273–282.
[28] S. Gilad, R. Khosravi, D. Shkedy, T. Uziel, Y. Ziv, K. Savitsky, G. Rotman, S. Smith, L.
Chessa, T.J. Jorgensen, R. Harnik, M. Frydman, O. Sanal, S. Portnoi, Z. Goldwicz, N.G.
Jaspers, R.A. Gatti, G. Lenoir, M.F. Lavin, K. Tatsumi, R.D. Wegner, Y. Shiloh, A. Bar-
Shira, Predominance of null mutations in ataxia-telangiectasia, Hum. Mol. Genet. 5
(1996) 433–439.
[29] T. Heinrich, C. Prowald, R. Friedl, B. Gottwald, R. Kalb, K. Neveling, S. Herterich, H.
Hoehn, D. Schindler, Exclusion/conﬁrmation of ataxia-telangiectasia via cell-cycle
testing, Eur. J. Pediatr. 165 (2006) 250–257.
[30] M. Mitui, C. Campbell, G. Coutinho, X. Sun, C.H. Lai, Y. Thorstenson, S. Castellvi-Bel, L.
Fernandez, E. Monros, B.T. Carvalho, O. Porras, G. Fontan, R.A. Gatti, Independent
mutational events are rare in the ATM gene: haplotype prescreening enhances mu-
tation detection rate, Hum. Mutat. 22 (2003) 43–50.
[31] S. Saviozzi, A. Saluto, A. Taylor, J. Last, F. Trebini, M. Paradiso, E. Grosso, A. Funaro, G.
Ponzio, N. Migone, A late onset variant of ataxia-telangiectasia with a compound het-
erozygous genotype, A8030G/7481insA, J. Med. Genet. 39 (2002) 57–61.
[32] S.P. Scott, R. Bendix, P. Chen, R. Clark, T. Dörk, M.F. Lavin,Missensemutations but not
allelic variants alter the function of ATM by dominant interference in patients with
breast cancer, Proc. Natl. Acad. Sci. 99 (2002) 925–930.
[33] P. Concannon, R.A. Gatti, Diversity of ATM gene mutations detected in patients with
ataxia-telangiectasia, Hum. Mutat. 10 (1997) 100–107.
[34] J.Wright, S. Teraoka, S. Onengut, A. Tolun, R.A. Gatti, H.D. Ochs, P. Concannon, A high
frequency of distinct ATM gene mutations in ataxia-telangiectasia, Am. J. Hum.
Genet. 59 (1996) 839–846.
[35] R. Micol, L. Ben Slama, F. Suarez, L. Le Mignot, J. Beaute, N. Mahlaoui, C. Dubois
d'Enghien, A. Lauge, J. Hall, J. Couturier, L. Vallee, B. Delobel, F. Rivier, K. Nguyen, T.
Billette de Villemeur, J.L. Stephan, P. Bordigoni, Y. Bertrand, N. Aladjidi, J.M. Pedespan,
C. Thomas, I. Pellier, M. Koenig, O. Hermine, C. Picard, D. Moshous, B. Neven, F.
Lanternier, S. Blanche, M. Tardieu, M. Debre, A. Fischer, D. Stoppa-Lyonnet, C.N.
Investigators, Morbidity and mortality from ataxia-telangiectasia are associated with
ATM genotype, J. Allergy Clin. Immunol. 128 (2011) 382–389 (e381).
216 M.A. Tabatabaiefar et al. / Journal of the Neurological Sciences 379 (2017) 212–216[36] N.D. Lakin, P.Weber, T. Stankovic, S.T. Rottinghaus, A.M. Taylor, S.P. Jackson, Analysis
of the ATM protein in wild-type and ataxia telangiectasia cells, Oncogene 13 (1996)
2707–2716.
[37] G.S. Stewart, J.I. Last, T. Stankovic, N. Haites, A.M. Kidd, P.J. Byrd, A.M. Taylor, Resid-
ual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia
patients, with 5762ins137 and 7271T–NG mutations, showing a less severe pheno-
type, J. Biol. Chem. 276 (2001) 30133–30141.
[38] M.M. Verhagen, W.F. Abdo, M.A. Willemsen, F.B. Hogervorst, D.F. Smeets, J.A. Hiel,
E.R. Brunt, M.A. van Rijn, D. Majoor Krakauer, R.A. Oldenburg, A. Broeks, J.I. Last,
L.J. van't Veer, M.A. Tijssen, A.M. Dubois, H.P. Kremer, C.M. Weemaes, A.M. Taylor,
M. van Deuren, Clinical spectrum of ataxia-telangiectasia in adulthood, Neurology
73 (2009) 430–437.[39] C.A. Ross, R. Truant, DNA repair: a unifying mechanism in neurodegeneration, Na-
ture 541 (2017) 34–35.
[40] Y. Huang, L. Yang, J.Wang, F. Yang, Y. Xiao, R. Xia, X. Yuan,M. Yan, Twelve novel Atm
mutations identiﬁed in Chinese ataxia telangiectasia patients, NeuroMolecular Med.
15 (2013) 536–540.
[41] K. Laake, M. Telatar, G.A. Geitvik, R.Ø. Hansen, A. Heiberg, A.M. Andresen, R. Gatti, A.-
L. Børresen-Dale, Identical mutation in 55% of the ATM alleles in 11 Norwegian AT
families: evidence for a founder effect, Eur. J. Hum. Genet. 6 (1998) 235–244.
[42] M. Saadat, M. Ansari-Lari, D. Farhud, Short report consanguineous marriage in Iran,
Ann. Hum. Biol. 31 (2004) 263–269.
